NEUROKINE

Serial Number 86023512
602

Registration Progress

Application Filed
Jul 30, 2013
Under Examination
Approved for Publication
Published for Opposition
Registered

Re-Apply for This Trademark

This trademark is no longer active. You may be able to file a new application for the same or similar mark.
Mark: NEUROKINE
Previous Owner: Mark Tarnopolsky
Classes: 005, 042

Trademark Image

NEUROKINE

Basic Information

Serial Number
86023512
Filing Date
July 30, 2013
Abandonment Date
September 8, 2017
Drawing Code
4000

Status Summary

Current Status
Inactive
Status Code
602
Status Date
Oct 8, 2017
Classes
005 042

Rights Holder

Mark Tarnopolsky

01
Address
19 Oakwood Place
Hamilton, Ontario L8S4C9
CA

Ownership History

Mark Tarnopolsky

Original Applicant
01
Hamilton, Ontario CA

Legal Representation

Attorney
Lori K. Hall

USPTO Deadlines

No Upcoming Deadlines

No upcoming deadlines found for this trademark.

Application History

38 events
Date Code Type Description Documents
Oct 10, 2017 MAB2 O ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND Loading...
Oct 8, 2017 ABN2 O ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE Loading...
Mar 7, 2017 GNS2 O NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED Loading...
Mar 7, 2017 GNSI S INQUIRY TO SUSPENSION E-MAILED Loading...
Mar 7, 2017 CNSI R SUSPENSION INQUIRY WRITTEN Loading...
Feb 15, 2017 RCCK S SUSPENSION CHECKED - TO ATTORNEY FOR ACTION Loading...
Aug 8, 2016 GNS3 O NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Loading...
Aug 8, 2016 GNSL S LETTER OF SUSPENSION E-MAILED Loading...
Aug 8, 2016 CNSL R SUSPENSION LETTER WRITTEN Loading...
Jul 21, 2016 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Jul 21, 2016 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Jul 13, 2016 ERSI I TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED Loading...
Jan 29, 2016 GNS2 O NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED Loading...
Jan 29, 2016 GNSI S INQUIRY TO SUSPENSION E-MAILED Loading...
Jan 29, 2016 CNSI R SUSPENSION INQUIRY WRITTEN Loading...
Jul 24, 2015 GNS3 O NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Loading...
Jul 24, 2015 GNSL S LETTER OF SUSPENSION E-MAILED Loading...
Jul 24, 2015 CNSL R SUSPENSION LETTER WRITTEN Loading...
Jul 21, 2015 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Jul 21, 2015 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Jul 14, 2015 ALIE A ASSIGNED TO LIE Loading...
Jul 7, 2015 ERSI I TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED Loading...
Jan 8, 2015 GNS2 O NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED Loading...
Jan 8, 2015 GNSI S INQUIRY TO SUSPENSION E-MAILED Loading...
Jan 8, 2015 CNSI R SUSPENSION INQUIRY WRITTEN Loading...
Dec 23, 2014 RCCK S SUSPENSION CHECKED - TO ATTORNEY FOR ACTION Loading...
Jun 20, 2014 GNS3 O NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Loading...
Jun 20, 2014 GNSL S LETTER OF SUSPENSION E-MAILED Loading...
Jun 20, 2014 CNSL R SUSPENSION LETTER WRITTEN Loading...
Jun 2, 2014 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Jun 2, 2014 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
May 23, 2014 ALIE A ASSIGNED TO LIE Loading...
May 9, 2014 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Nov 14, 2013 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Nov 14, 2013 GNRT F NON-FINAL ACTION E-MAILED Loading...
Nov 14, 2013 CNRT R NON-FINAL ACTION WRITTEN Loading...
Nov 13, 2013 DOCK D ASSIGNED TO EXAMINER Loading...
Aug 6, 2013 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical preparation for treating neurological diseases, neurosurgical conditions, neuropsychological diseases and disorders, and neuro-degenerative disorders and diseases; pharmaceutical, namely, oral, inhalational, parenteral, topical pharmaceuticals containing proteins, protein kinase orphosphatas; nutraceuticals, vitamins, minerals, nutritional and dietary supplements for the treatment of all skin diseases and disorders
First Use Anywhere: 0
First Use in Commerce: 0
Class 042
Medical and scientific research in the field of neurological diseases, neurosurgical conditions, neuropsychological diseases and disorders, and neuro-degenerative disorders and diseases; Medical research; Pharmaceutical research and development
First Use Anywhere: 0
First Use in Commerce: 0

Classification

International Classes
005 042